美国 COVID-19 大流行期间常用药物的处方配药模式。
Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.
机构信息
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
GoodRx, Santa Monica, California.
出版信息
JAMA. 2020 Jun 23;323(24):2524-2526. doi: 10.1001/jama.2020.9184.
Abstract
This pharmacoepidemiology study uses US pharmacy data to compare prescriptions for hydroxychloroquine/chloroquine and azithromycin in February to April 2020 vs 2019, and vs the top 10 most commonly prescribed drugs in the same year, including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
摘要
这项药物流行病学研究利用美国的药房数据，对比了 2020 年 2 月至 4 月与 2019 年同期，以及与同年开处方最多的 10 种药物（包括血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂）相比，羟氯喹/氯喹和阿奇霉素的处方情况。
相似文献
1
Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.美国 COVID-19 大流行期间常用药物的处方配药模式。
JAMA. 2020 Jun 23;323(24):2524-2526. doi: 10.1001/jama.2020.9184.
2
The Landscape of Prescription Drug Shortages During the COVID-19 Pandemic.新冠疫情期间处方药短缺的情况
J Med Toxicol. 2020 Jul;16(3):311-313. doi: 10.1007/s13181-020-00786-4. Epub 2020 May 27.
3
[Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness].[羟氯喹和氯喹治疗新冠病毒病：无有效性证据]
Ned Tijdschr Geneeskd. 2020 Jun 2;164:D5141.
4
Regulators split on antimalarials for COVID-19.监管机构在用于治疗新冠肺炎的抗疟疾药物问题上存在分歧。
Lancet. 2020 Apr 11;395(10231):1179. doi: 10.1016/S0140-6736(20)30817-5.
5
Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.用于治疗新冠肺炎的氯喹/羟氯喹引发室性心律失常的风险：是否应该使用该药？
Indian Heart J. 2020 Mar-Apr;72(2):131-132. doi: 10.1016/j.ihj.2020.04.006. Epub 2020 Apr 27.
6
COVID-19 and Depression.新型冠状病毒肺炎与抑郁症。
Clin Ther. 2020 Jun;42(6):962-963. doi: 10.1016/j.clinthera.2020.04.010. Epub 2020 Apr 27.
7
COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits.新型冠状病毒肺炎与抗疟药物：弊大于利
Am J Crit Care. 2020 Nov 1;29(6):489-492. doi: 10.4037/ajcc2020694.
8
Of chloroquine and COVID-19.关于氯喹和 COVID-19。
Antiviral Res. 2020 May;177:104762. doi: 10.1016/j.antiviral.2020.104762. Epub 2020 Mar 5.
9
The COVID-19 Pandemic and Mayo Clinic Proceedings.新冠疫情与《梅奥诊所学报》
Mayo Clin Proc. 2020 May;95(5):835-836. doi: 10.1016/j.mayocp.2020.04.009. Epub 2020 Apr 18.
10
Meta-analysis of Effect of Statins in Patients with COVID-19.他汀类药物对新型冠状病毒肺炎患者影响的荟萃分析
Am J Cardiol. 2020 Nov 1;134:153-155. doi: 10.1016/j.amjcard.2020.08.004. Epub 2020 Aug 12.
引用本文的文献
1
Acute Hydroxychloroquine Overdose With Severe and Prolonged Cardiotoxicity.急性羟氯喹过量导致严重且持久的心脏毒性。
Cureus. 2025 Jul 22;17(7):e88512. doi: 10.7759/cureus.88512. eCollection 2025 Jul.
2
Nomogram-based risk prediction model employing serum biomarkers to assess intestinal injury risk in patients with metabolic syndrome.基于列线图的风险预测模型，采用血清生物标志物评估代谢综合征患者的肠道损伤风险。
Front Endocrinol (Lausanne). 2025 Jun 16;16:1579833. doi: 10.3389/fendo.2025.1579833. eCollection 2025.
3
Rethinking the Impact of Single Continuing Educational Activities: Navigating Complexity Through Insights from Real-World Evaluation and Contemporary Literature.重新思考单一继续教育活动的影响：通过来自现实世界评估和当代文献的见解应对复杂性
J CME. 2025 May 12;14(1):2498292. doi: 10.1080/28338073.2025.2498292. eCollection 2025.
4
Trends in medication use during the COVID-19 pandemic in Quebec, Canada.加拿大魁北克省新冠疫情期间的用药趋势。
Sci Rep. 2025 Apr 27;15(1):14744. doi: 10.1038/s41598-025-98592-x.
5
Evaluating the utilisation patterns of pharmacological therapy in COVID-19 patients: an ecological study in Italy.评估新冠病毒肺炎患者药物治疗的使用模式：意大利的一项生态学研究
BMJ Public Health. 2025 Feb 26;3(1):e001767. doi: 10.1136/bmjph-2024-001767. eCollection 2025 Jan.
6
Evidence-informed language: interpretation and impact on intentions to treat - results of an online survey of medical students and specialists in German-speaking countries.循证语言：解释及其对治疗意向的影响——对德语国家医学生和专家的在线调查结果
BMJ Open. 2025 Feb 7;15(2):e082907. doi: 10.1136/bmjopen-2023-082907.
7
Evaluation of link between COVID-19 adjacent spike in hydroxychloroquine use and increased reports of pemphigus: a disproportionality analysis of the FDA Adverse Event Reporting System.评估羟氯喹使用量的新冠相关激增与天疱疮报告增加之间的关联：对美国食品药品监督管理局不良事件报告系统的不成比例性分析
Front Immunol. 2024 Dec 20;15:1470660. doi: 10.3389/fimmu.2024.1470660. eCollection 2024.
8
Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials.伊维菌素、氯喹/羟氯喹及阿奇霉素治疗新冠肺炎的疗效：III期临床试验的系统评价
Biomedicines. 2024 Sep 27;12(10):2206. doi: 10.3390/biomedicines12102206.
9
Elevated circulating regenerating islet-derived protein 4 levels in patients with metabolic syndrome and related to its key components.代谢综合征患者循环中再生胰岛衍生蛋白4水平升高，且与代谢综合征的关键组分相关。
Endocrine. 2025 Feb;87(2):578-588. doi: 10.1007/s12020-024-04056-z. Epub 2024 Oct 16.
10
Beyond misinformation: developing a public health prevention framework for managing information ecosystems.超越错误信息：制定公共卫生预防框架以管理信息生态系统。
Lancet Public Health. 2024 Jun;9(6):e397-e406. doi: 10.1016/S2468-2667(24)00031-8. Epub 2024 Apr 20.
本文引用的文献
1
Internet Searches for Unproven COVID-19 Therapies in the United States.互联网上对未经证实的新冠病毒治疗方法的搜索情况。
JAMA Intern Med. 2020 Aug 1;180(8):1116-1118. doi: 10.1001/jamainternmed.2020.1764.
2
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
3
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
Zotero 插件